Streetbeat News

Products Services

REPL

Replimune Group shares are trading higher following the announcement of positive topline results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 2:24 pm

SAM

Green Thumb Industries (GTI) is reportedly seeking a merger with Boston Beer Company, which could allow GTI to list on a major exchange and enter the Hemp THC beverage market. This move could boost the credibility of the cannabis sector and attract traditional alcohol investors.

Portfolio Pulse from Nicolás Jose Rodriguez

June 06, 2024 | 2:21 pm

GHBWF

GLASF

Michigan has surpassed California in legal cannabis unit sales, selling 22 million products in March compared to California's 21.3 million. Despite California leading in revenue, high taxes and weak enforcement against illegal sales have hurt its market. Michigan's lower taxes and strong enforcement have boosted its legal market, attracting out-of-state customers. California's cannabis industry faces significant challenges, including rampant illegal operations and environmental damage.

Portfolio Pulse from Patricio Liddle

June 06, 2024 | 2:16 pm

XYL

TPU has deployed Xylem's Advanced Metering Infrastructure (AMI) technology to enhance operational efficiency and customer service. The network delivers 6.5 million daily reads, enabling frequent billing and improved response times.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 2:16 pm

AAPL

GOOGL

INTC

IVV

META

MSFT

NVDA

SPY

TSM

Nvidia Corp (NASDAQ:NVDA) stock surged to record highs, valuing the company at over $3 trillion. Nvidia plans a ten-for-one stock split on June 7 to attract more individual investors. The company's valuation has soared 147% in 2024 due to strong demand for AI processors. Nvidia added nearly $150 billion in market capitalization on Wednesday. The company is preparing to ramp up investments in Taiwan and is considering Intel Corp (NASDAQ:INTC) as a potential supplier. Nvidia stock gained over 217% in the last 12 months.

Portfolio Pulse from Anusuya Lahiri

June 06, 2024 | 2:14 pm

ADBE

Adobe's updated Terms of Service have sparked discussions among traders on social media. The new terms clarify that Adobe may access user content through both automated and manual methods for content review.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 2:11 pm

INTC

NVDA

SMCI

TSM

Intel and Sharp are collaborating to innovate chip production and cut costs by using Sharp's underutilized LCD plants in Japan. This partnership will help Intel focus on back-end chip production processes and provide Sharp with needed income. Nvidia is considering Intel as a potential supplier, while TSMC faces supply chain constraints and plans to hike prices. Intel aims to enhance its AI chip offerings, potentially generating significant revenue in 2024.

Portfolio Pulse from Anusuya Lahiri

June 06, 2024 | 2:11 pm

LIVN

LivaNova shares are trading lower after the company's RECOVER clinical study did not meet its primary endpoint for the unipolar cohort, though statistical significance was achieved in select secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 2:10 pm

AAPL

GOOGL

META

MSFT

NVDA

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo for June 6th, 2024, provides a detailed analysis of key price levels for SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA. The memo outlines potential bullish and bearish scenarios for each asset, emphasizing the importance of monitoring these levels closely. The memo also highlights the impact of the European Central Bank's rate decision and other economic data releases on market sentiment and volatility.

Portfolio Pulse from RIPS

June 06, 2024 | 2:10 pm

MAIA

MAIA Biotechnology has announced significant year-to-date achievements, including clinical progress of its lead candidate THIO, a first-in-class cancer telomere targeting agent for non-small cell lung cancer (NSCLC). The company has secured over $12 million in funding, with $7.4 million raised in Q2'24. THIO has shown exceptional efficacy in Phase 2 clinical trials, with a 38% overall response rate and a median progression-free survival of 5.5 months, outperforming current standard-of-care treatments.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 2:08 pm